Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219307 | 0.83 | SLC6A2 (0.42) | TSHRTDP1PTGER1CCNA2CDK2 | |
| SCHEMBL14422265 | 0.78 | HDAC1 (0.43) | TDP1LMNAMEN1KMT2A | |
| SCHEMBL11910638 | 0.78 | CES1 (0.50) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL14422264 | 0.76 | SMN1; SMN2 (0.47) | KDM4ETDP1LMNA | |
| SCHEMBL14422204 | 0.75 | TRPV1 (0.46) | RORCLMNA | |
| SCHEMBL1811036 | 0.73 | CES1 (0.38) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL13685198 | 0.72 | IGFBP3 (0.39) | PTGER1CES1 | |
| SCHEMBL742811 | 0.71 | CES1 (0.39) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1707161 | 0.71 | LMNA (0.43) | PTGER1CES1MRGPRX4KLKB1LMNA | |
| SCHEMBL2868442 | 0.70 | NOTUM (0.46) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1603905-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004072068-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KDM4E 4111/4885ALOX15 523/4885TSHR 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.